BioStem Technologies Inc BSEM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BSEM is a good fit for your portfolio.
News
-
BioStem Technologies to Present at the 2024 Planet MicroCap Showcase
-
BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior Exchange
-
BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference
-
BioStem Technologies Reports Fourth Quarter Revenue of $11.5 Million, 14-Fold YoY Increase
-
BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024
-
PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market
Trading Information
- Previous Close Price
- $9.11
- Day Range
- $9.14–9.39
- 52-Week Range
- $1.20–15.50
- Bid/Ask
- $9.13 / $9.30
- Market Cap
- $121.83 Mil
- Volume/Avg
- 25,089 / 29,374
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 20.43
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The Company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AmnioWrap2.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 2
Valuation
|
Metric
|
BSEM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 20.43 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BSEM
|
|---|---|
Quick Ratio | 0.38 |
Current Ratio | 0.48 |
Interest Coverage | −16.99 |
Quick Ratio
BSEM
Profitability
|
Metric
|
BSEM
|
|---|---|
Return on Assets (Normalized) | −52.95% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −122.00% |
Return on Assets
BSEM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Kldbrfzsz | Zfjd | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vhbtghp | Jhrwfg | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Znmdsdsy | Fthfm | $98.3 Bil | |
MRNA
| Moderna Inc | Bbsrhcyqd | Mbqx | $42.7 Bil | |
ARGX
| argenx SE ADR | Gwyhdkbl | Mhv | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Jvfwywj | Hqmm | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Chjhwbxl | Hrmlfwz | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lpfklps | Xxxnjy | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vgbwykjyc | Bnksgg | $12.7 Bil | |
INCY
| Incyte Corp | Lctlmsqk | Rqymfl | $11.8 Bil |